Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study of Setileuton [MK0633] in Adult Patients With Chronic Asthma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Setileuton (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Merck & Co
- 08 Nov 2011 Additional trial locations (Czech Republic, Hungary) identified as reported by European Clinical Trials Database.
- 02 Jun 2009 Actual patient number (688) added as reported by ClinicalTrials.gov.
- 02 Jun 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.